Medicare Approval Expands Access to Personalis’ Ultrasensitive MRD Test for Breast Cancer Recurrence
Major Coverage Milestone Enables Wider Use in Breast Cancer Surveillance
Personalis (NASDAQ: PSNL) today announced that its NeXT Personal® test—designed for ultrasensitive detection of cancer recurrence—has secured Medicare coverage for breast cancer surveillance. This pivotal development allows Medicare beneficiaries with stage II and III breast cancer—including HR+/HER2-, HER2+, and triple-negative breast cancer (TNBC)—to access NeXT Personal for up to six years following initial treatment.
Early Recurrence Detection Backed by Strong Clinical Data
The approval follows the publication of a study in the Annals of Oncology demonstrating that NeXT Personal could identify all breast cancer recurrences up to five years ahead of standard-of-care imaging, with a median lead time of approximately 15 months. Significantly, every patient who tested negative during the surveillance period remained disease-free. These findings point to the test's value not only for catching recurrence earlier but also for providing patients added peace of mind after treatment.
| Key Attribute | Details |
|---|---|
| Medicare Coverage | Stage II and III breast cancer (HR+/HER2-, HER2+, TNBC) |
| Surveillance Period | Up to 6 years post-treatment |
| Clinical Sensitivity | Detected 100% of recurrences; median lead time of 15 months (up to 5 years) ahead of imaging |
| Negative Predictive Value | 100% of negative results remained disease-free |
Test Adoption and Strategic Impact
The inclusion of the NeXT Personal test in Medicare coverage not only expands its availability to thousands of additional patients, but also serves as a significant external validation of Personalis’ technological approach. “This coverage allows us to expand access to the NeXT Personal test, supporting breast cancer patients who often live with the constant worry of cancer recurrence after treatment,” stated Dr. Richard Chen, Personalis CMO and EVP of R&D.
The CEO of Personalis, Chris Hall, highlighted that the test’s unique ultra-sensitivity fills a key unmet need in oncology and called Medicare’s decision a powerful step toward transforming cancer management and personalizing care across the entire patient journey.
Market Reaction: Strong Sentiment Around Potential and Broader Impact
While the press release was issued mid-market, shares of Personalis traded at $8.90, up by 28.43% at 10:33 AM—underscoring optimism over the coverage decision. Investors appear focused on both the immediate revenue opportunity from increased Medicare utilization and the long-term strategic implications for the MRD testing landscape.
Takeaway: An Important Step in Precision Oncology
The newly approved Medicare coverage may prove a catalyst for wider clinical adoption of the NeXT Personal test and signals rising acceptance of highly sensitive, blood-based surveillance methods in cancer care. For stakeholders tracking innovation in oncology diagnostics, Personalis’ coverage milestone warrants close attention—not only for its commercial implications but also for its potential to reshape breast cancer management protocols going forward.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI